PartnershipUpdated on 23 November 2025
Small molecules inhibiting SARS-coronavirus infections
Group Leader at Max Delbrück Center for Molecular Medicine
Berlin, Germany
About
Using a novel assay, we have screened a 100.000 compound library for molecules inhibiting the binding of SARS-CoV2 to its receptor ACE2 and identified and validated 6 hits, which are optimized further by medicinal chemistry. The objective is to develop an inexpensive, preventive, oral or inhalative drug for COVID-19 and other coronavirus infections.
Looking for
- Joint development
- Technology transfer
Organisation
Similar opportunities
Partnership
Selective Inhibitors of Genotoxic Stress Induced NFκB Pathway for Cancer Therapy
- Research
- Joint development
- Testing of technology
Beatrice Pöschel
Technologie-Managerin at Max Delbrück Center for Molecular Medicine
Berlin, Germany
Investment
Selective Inhibitors of Genotoxic Stress Induced NFκB Pathway for Cancer Therapy
- Disease Area
- Seed & Development
- Biomedical Research, Medicine, Human Health
Beatrice Pöschel
Technologie-Managerin at Max Delbrück Center for Molecular Medicine
Berlin, Germany